Back to Search
RUDOLPH NAVARI, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1891778023IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
8424(AL)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
8424(AL)
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
8424(AL)
Education
OTHER
Class of 1977
Research & Publications (20)
Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
PMID 19284365·Expert Opin Pharmacother·2009
6-review
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy.
PMID 18064563·Breast Cancer Res Treat·2008
2-rct
Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
PMID 18983233·Expert Rev Anticancer Ther·2008
6-review
Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
PMID 18600583·Curr Opin Investig Drugs·2008
6-review
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
PMID 17375339·Support Care Cancer·2007
3-trial
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
PMID 15700131·Support Care Cancer·2005
3-trial
Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists.
PMID 18628185·Support Cancer Ther·2004
8-other
Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
PMID 15565815·Cancer Invest·2004
4-observational
Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
PMID 15485308·Expert Rev Anticancer Ther·2004
6-review
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
PMID 12921512·Ann Pharmacother·2003
4-observational
Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
PMID 19368415·Drugs·2009
6-review
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
PMID 17239326·J Natl Compr Canc Netw·2007
6-review
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
PMID 18042005·Expert Opin Investig Drugs·2007
6-review
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
PMID 17026451·Future Oncol·2006
6-review
Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting.
PMID 16427741·Cancer Treat Rev·2006
8-other
Cathepsin E is a specific marker of dysplasia in APC mouse intestine.
PMID 16340248·Tumour Biol·2006
7-preclinical
Symptomatic treatment of infections in patients with advanced cancer receiving hospice care.
PMID 16125033·J Pain Symptom Manage·2005
8-other
Highlights from: The 40th Annual Meeting of the American Society of Clinical Oncology; New Orleans, LA.
PMID 18628142·Support Cancer Ther·2004
8-other
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
PMID 15493359·Cancer Invest·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 832 PRINCETON AVE SW
BIRMINGHAM, AL 35211 - Phone
- (205) 397-8934
Quick Facts
- NPI
- 1891778023
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 2
- Years in Practice
- 49
- Publications
- 20
Are you this provider?
Claim Your Profile